Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.06.24 | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) | 246 | GlobeNewswire (Europe) | Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening... ► Artikel lesen | |
16.06.24 | Regeneron Pharmaceuticals, Inc.: Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma | 382 | GlobeNewswire (Europe) | At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 601 |
EVOTEC | 334 |
NOVO NORDISK | 323 |
TESLA | 291 |
RHEINMETALL | 246 |
BYD | 233 |
RENK GROUP | 170 |
DEUTZ | 162 |
TUI | 135 |
APPLE | 132 |
BASF | 132 |
VOLKSWAGEN | 130 |
STEYR MOTORS | 128 |
NETFLIX | 127 |
BAYER | 126 |
PLUG POWER | 122 |
AMAZON | 117 |
UNITEDHEALTH | 114 |
ALMONTY | 113 |
XIAOMI | 108 |
COMMERZBANK | 107 |
E.ON | 105 |
NEL | 105 |
RWE | 105 |
SIEMENS ENERGY | 100 |